IgA Vasculitis following AstraZeneca/Oxford COVID-19, case report
We report a case of IgA vasculitis after AstraZeneca/Oxford COVID-19 vaccine. A 29-year-old healthy man who developed purpuric skin lesions one week after his second AstraZeneca/Oxford COVID-19 vaccine which complicated by glomerulonephritis and gastrointestinal involvement. Skin biopsy revealed fibrinoid necrosis and leukocytoclasia consistent with small vessel vasculitis. Due to the temporal association, AstraZeneca/Oxford COVID-19 vaccine-related IgA vasculitis would be the most likely explanation.PMID:38054690 | PMC:PMC10734242 | DOI:10.23750/abm.v94i6.12959 (Source: Acta Bio-Medica : Atenei Parmensis)
Source: Acta Bio-Medica : Atenei Parmensis - December 6, 2023 Category: General Medicine Authors: Nasser Alzoabi Jamal Alqahtani Bader Algamdi Nada Alghamdi Ayesha Ahmad Gaeda Alkaltham Tala Beidas Omar Alakloby Source Type: research
HPR201 Lessons from the COVID-19 Vaccines Taskforce
The Vaccines Task Force (VTF) was established by the UK government in April 2020, with the objective of securing early access to effective COVID-19 vaccines for the UK population and internationally. The VTF was successful in securing the earliest access to the Oxford/Astra Zeneca and Pfizer/BioNTech vaccines, allowing the UK to be the first country in the world to deploy an approved COVID-19 vaccine. The VTF also played a critical role in supporting efforts to distribute vaccines globally, as one of COVAX ’s earliest and largest donors. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: E. Bell, J. Van-Tam, R. Todd, S. Carroll Source Type: research
HSD44 Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated With Benralizumab in Real-Life: Results From the Portuguese BETREAT Study
This study is part of AstraZeneca ’s global XALOC real-world evidence program. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C. Chaves-Loureiro, F. Carri ço, U. Brito, I. Belchior, R.A. Fernandes, N. Sousa, A. Mendes, C. Loureiro, C. Pardal, L. Ribeiro, G. Reis, N. Pires, C. Teles, J. Plácido, R. Boaventura, R. Lima, M. Pardal, A. Marques, H. Martinho, F. Bernardo Source Type: research
HTA304 The Impact of Different HTA Frameworks on Time to Patient Access: A Case Study Assessing the First Commercial Launch Indications for Lynparza, Tagrisso, Imfinzi, Calquence and Enhertu
• To compare payer/ regulator assessments for 5 AstraZeneca cancer medicines in the context of clinical uncertainty • To quantify time to patient access • To identify potential improvements for the medicine access pathway, during long-term clinical benefit uncertainty (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: B. Crean, D. Parry, A. Horsfield, J. Ryan, N. Oraiopoulos Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
UK Biobank releases half a million whole-genome sequences for biomedical research
One of the world’s largest databases of whole genomes has just become a lot larger. The British health study known as the UK Biobank today made the full genetic sequences of nearly 500,000 people available to scientists for analysis, more than doubling the size of an earlier data set. Combined with long-term health data on participants, this “treasure trove” has the potential to transform biomedical science, organizers say.
Geneticists are excited by the news. Such a large set of sequences provides a uniquely rich resource for studying the biological underpinnings of human health and disease, says Eleftheria Ze...
Source: Science of Aging Knowledge Environment - November 30, 2023 Category: Geriatrics Source Type: research
IJERPH, Vol. 20, Pages 7123: Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021
We present self-reported adverse events (AE) following the receipt of these vaccines in Malawi as part of a national syndromic surveillance survey. We conducted phone-based syndromic surveillance surveys among adults (≥18 years) with verbal consent. We used secure tablets through random digit dialing to select mobile phone numbers and collected data electronically. Survey questions included whether the respondent had received the COVID-19 vaccines, whether they had experienced any AE following vaccination, and the severity of the AE. We used multivariable analysis to identify factors associated with self-reporte...
Source: International Journal of Environmental Research and Public Health - November 30, 2023 Category: Environmental Health Authors: Lucky Makonokaya Lester Kapanda Godfrey B. Woelk Annie Chauma-Mwale Louiser Upile Kalitera Harrid Nkhoma Suzgo Zimba Rachel Chamanga Cathy Golowa Rhoderick Machekano Thulani Maphosa Tags: Article Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
AbstractRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis ™–AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that include vaccines and long-acting, high-potency monoclonal antibodies. Ni rsevimab (Beyf...
Source: Pediatric Drugs - November 30, 2023 Category: Pediatrics Source Type: research
Viruses, Vol. 15, Pages 2319: Development of an Oral IgA Response against SARS-CoV-2 following Immunization with Different COVID-19 Vaccines
Elisabetta Caselli
The mucosal immune response is recognized to be important in the early control of infection sustained by viruses with mucosal tissues as the primary site of entry and replication, such as SARS-CoV-2. Mucosal IgA has been consistently reported in the mouth and eye of SARS-CoV-2 infected subjects, where it correlated inversely with COVID-19 symptom severity. Yet, there is still scarce information on the comparative ability of the diverse SARS-CoV-2 vaccines to induce local IgA responses at the virus entry site. Thus, the aim of this study was to assess the presence of anti-SARS-CoV-2 IgA in the saliva ...
Source: Viruses - November 25, 2023 Category: Virology Authors: Irene Soffritti Maria D ’Accolti Francesca Bini Eleonora Mazziga Davide Proietto Beatrice Dallan Martina De Laurentis Sara Ghisellini Francesco Nicoli Elisabetta Caselli Tags: Article Source Type: research
Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency
DiscussionThe Covid-19 vaccines appear well-tolerated in patients with AI, with similar frequency of symptoms to that reported in the background population. The AZ vaccine leads to slightly greater post-vaccination symptom burden and need to increase glucocorticoid dosage, but this does not translate to greater adverse outcomes. (Source: Pituitary)
Source: Pituitary - November 17, 2023 Category: Endocrinology Source Type: research
